Processa Pharmaceuticals (NASDAQ:PCSA) Releases Earnings Results, Beats Expectations By $0.47 EPS

Processa Pharmaceuticals (NASDAQ:PCSA) issued its quarterly earnings results on Friday. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.47, Zacks reports.

Processa Pharmaceuticals Price Performance

NASDAQ PCSA opened at $0.24 on Friday. The stock has a market capitalization of $1.25 million, a price-to-earnings ratio of -0.07 and a beta of 1.36. The business’s fifty day moving average is $0.33 and its 200-day moving average is $0.69. Processa Pharmaceuticals has a one year low of $0.15 and a one year high of $3.10.

Processa Pharmaceuticals Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.